Page last updated: 2024-10-17

bupropion and Frigidity

bupropion has been researched along with Frigidity in 48 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research Excerpts

ExcerptRelevanceReference
" We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants."9.09Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001)
" We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants."5.09Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001)
"Outpatients with moderate to severe major depressive disorder (DSM-IV) received bupropion SR (100-300 mg/day) or sertraline (50-200 mg/day) for 16 weeks."5.08Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. ( Ascher, JA; Hughes, AR; Johnston, JA; Kavoussi, RJ; Segraves, RT, 1997)
" Bupropion is less likely than other antidepressants to cause weight gain and sexual dysfunction, the 2 side effects that are of greatest concern to patients and that have the greatest impact on long-term compliance."4.82Why isn't bupropion the most frequently prescribed antidepressant? ( Attiullah, N; Baymiller, S; Berlowitz, SL; Boland, RJ; Chelminski, I; Friedman, M; Posternak, MA; Rahman, S; Singer, S; Uy, KK; Zimmerman, M, 2005)
"Bupropion was not more effective than placebo in improving the desire subscale of the FSFI."3.11Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004. ( Balcueva, EP; Barton, DL; Basil, JB; Bell, MC; Carter, J; Deshmukh, S; Ganz, PA; Greyz-Yusupov, N; Hill, ML; Kachnic, LA; Koontz, BF; Muller, CY; Nabeel, S; Page, SJ; Plaxe, SC; Pugh, SL; Rowland, KM, 2022)
"Prior medication treatment for hypoactive sexual desire disorder (HSDD) in women has left about half the subjects without benefit."2.90Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women. ( Clayton, AH; Pyke, RE, 2019)
" A meta-regression was performed to explore heterogeneity and we found that only the dosage of bupropion was statistically significant in explaining the variance, i."2.82The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis. ( Baharudin, A; Choy, CL; Das, S; Razali, NA; Roos, NAC; Sidi, H, 2022)
" A total of 218 women (25-45 years old) with SSRI-induced sexual dysfunction were randomized to receive 12 weeks of double-blind fixed dosed treatment with bupropion sustained release 150 mg b."2.76Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. ( Safarinejad, MR, 2011)
"Bupropion is an effective treatment for male SD induced by SSRIs."2.75The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study. ( Safarinejad, MR, 2010)
"Bupropion is an antidepressant with fewer reported adverse sexual effects."2.70Effects of bupropion sustained-release on sexual functioning and nocturnal erections in healthy men. ( Arana, GW; Brodrick, PS; Labbate, LA; Lydiard, RB; Nelson, RP, 2001)
"The etiology of hypoactive sexual desire disorder is multifactorial and its management requires a combination of psychosocial and pharmacological interventions."2.47Managing low sexual desire in women. ( Maclaran, K; Panay, N, 2011)
"Antidepressant-induced adverse sexual effects are becoming more frequently reported by patients who require pharmacotherapy."2.39Sexual side effects of antidepressants: a review. ( Assalian, P; Margolese, HC, 1996)
"Major depressive disorder (MDD) and type 2 diabetes have independent adverse effects on sexual functioning (SF)."1.37Improvement in sexual functioning in patients with type 2 diabetes and depression treated with bupropion. ( Gott, BM; Lustman, PJ; Nix, BD; Sayuk, GS, 2011)
"Bupropion SR as a treatment for depression also alleviates sexual dysfunction due to SSRI treatment."1.31Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. ( Abouesh, AI; Clayton, AH; McGarvey, EL; Pinkerton, RC, 2001)

Research

Studies (48)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.08)18.7374
1990's13 (27.08)18.2507
2000's21 (43.75)29.6817
2010's10 (20.83)24.3611
2020's3 (6.25)2.80

Authors

AuthorsStudies
Barton, DL1
Pugh, SL1
Ganz, PA1
Plaxe, SC1
Koontz, BF1
Carter, J1
Greyz-Yusupov, N1
Page, SJ1
Rowland, KM1
Balcueva, EP1
Nabeel, S1
Basil, JB1
Hill, ML1
Muller, CY1
Bell, MC1
Deshmukh, S1
Kachnic, LA1
Razali, NA1
Sidi, H1
Choy, CL1
Roos, NAC1
Baharudin, A1
Das, S1
Pyke, RE1
Clayton, AH5
Ramli, FF1
Azizi, MH1
Syed Hashim, SA1
Lodise, NM1
Safarinejad, MR3
Hosseini, SY1
Asgari, MA1
Dadkhah, F1
Taghva, A1
DeRogatis, LR1
Sayuk, GS1
Gott, BM1
Nix, BD1
Lustman, PJ1
Maclaran, K1
Panay, N1
Calandra, C1
Russo, RG1
Luca, M1
Hartmann, UH1
Rüffer-Hesse, C1
Krüger, TH1
Philippsohn, S1
Warnock, JK1
Biggs, CF1
Chollet, CA1
Andreatini, R1
Segraves, RT4
Clayton, A1
Croft, H2
Wolf, A1
Warnock, J1
Zimmerman, M1
Posternak, MA1
Attiullah, N1
Friedman, M1
Boland, RJ1
Baymiller, S1
Berlowitz, SL1
Rahman, S1
Uy, KK1
Singer, S1
Chelminski, I1
DeBattista, C1
Solvason, B1
Poirier, J1
Kendrick, E1
Loraas, E1
Menaster, MJ1
Dobkin, RD1
Menza, M1
Marin, H1
Allen, LA1
Rousso, R1
Leiblum, SR1
Basson, R1
Brotto, LA1
Laan, E1
Redmond, G1
Utian, WH1
Csoka, AB1
Shipko, S1
Croft, HA1
Horrigan, JP1
Wightman, DS1
Krishen, A1
Richard, NE1
Modell, JG2
Montejo, AL1
Thase, ME1
Haight, BR1
Thompson, AH1
Johnston, JA3
Jefferson, JW1
Segraves, KB1
Bubna, CN1
Walker, PW1
Cole, JO1
Gardner, EA1
Hughes, AR2
Batey, SR3
Lineberry, CG1
Margolese, HC1
Assalian, P1
Kavoussi, RJ1
Ascher, JA3
Labbate, LA3
Grimes, JB1
Hines, A1
Pollack, MH1
Ashton, AK2
Rosen, RC1
Dewan, MJ1
Anand, VS1
Settle, E1
Houser, T1
Donahue, RM2
Hirschfeld, RM1
Coleman, CC1
Cunningham, LA1
Foster, VJ1
Houser, TL1
Ramasubbu, R1
Brodrick, PS1
Nelson, RP1
Lydiard, RB1
Arana, GW1
Zajecka, J1
Ferguson, JM1
McGarvey, EL1
Abouesh, AI1
Pinkerton, RC1
Masand, PS1
Gupta, S1
Frank, B1
Chengappa, KN1
Kambhampati, RK1
Perkins, K1
Nigam, R1
Anderson, T1
Brar, JS1
Vemulapalli, HK1
Atzert, R1
Key, P1
Kang, JS1
Levine, J1
Hierholzer, R1
Crenshaw, TL1
Goldberg, JP1
Stern, WC1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer[NCT03180294]Phase 2230 participants (Actual)Interventional2017-05-31Completed
A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/Day) and Exte[NCT00316160]Phase 4347 participants Interventional2004-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"Change From Baseline at 5 Weeks in Desire Subscore of the FSFI (Sexual Desire)"

"The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as sexual desire in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 weeks from start of study treatment (within 21 days of randomization)

Interventionunits on a scale (Mean)
Bupropion 150 mg0.70
Bupropion 300 mg0.48
Placebo0.58

"Change From Baseline at 9 Weeks in the Desire Subscore of the Female Sexual Function Index (Sexual Desire)"

"The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as sexual desire in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 9 weeks from start of study treatment (within 21 days of randomization)

Interventionunits on a scale (Mean)
Bupropion 150 mg0.64
Bupropion 300 mg0.60
Placebo0.62

Number of Participants With a Grade 3 or Higher Adverse Event Over the Course of the Study

Common Terminology Criteria for Adverse Events (version 4) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure.; see Adverse Events Module for specific adverse event data. (NCT03180294)
Timeframe: Adverse events were evaluated 1,2,5,7, and 9 weeks from start of study treatment (within 21 days of randomization).

InterventionParticipants (Count of Participants)
Bupropion 150 mg4
Bupropion 300 mg1
Placebo3

"Change From Baseline in FSFI Total Score (Sexual Functioning)"

"The FSFI total score measures self-reported female sexual functioning covering the major domains arousal, satisfaction, and orgasm, and including lubrication and pain. Possible scores range from 2 to 36, with higher scores indicating better functioning. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased functioning. This measure is referred to as sexual functioning in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization)

,,
Interventionunits on a scale (Mean)
Week 5Week 9
Bupropion 150 mg3.843.29
Bupropion 300 mg4.013.55
Placebo3.534.70

"Change From Baseline in the Patient Health Questionnaire (PHQ)-4 Score (Depressive Mood)"

"The PHQ-4 is a brief screening questionnaire for depression. Possible scores range from 0 to 12, with higher scores indicating more severe depression. Change score is calculated by subtracting baseline from later score, with a negative change score indicating decreased severity of depression. This measure is referred to as depressive mood in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization)

,,
Interventionunits on a scale (Mean)
Week 5Week 9
Bupropion 150 mg-0.44-0.42
Bupropion 300 mg-0.17-0.43
Placebo-0.16-0.43

"Change From Baseline in the PROMIS Global Satisfaction With Sex Life Subscore of Sexual Function and Satisfaction Measure (Sexual Desire and Satisfaction)"

"The PROMIS Global Satisfaction with Sex Life subscore measures self-reported global satisfaction, interest, and interference in sexual health over the past 7 days. Possible scores range from 3 to 30, with higher scores indicating more satisfaction with sex life. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased satisfaction. This score is referred to as the PROMIS sexual desire and satisfaction measure in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization)

,,
Interventionunits on a scale (Mean)
Week 5Week 9
Bupropion 150 mg3.352.05
Bupropion 300 mg2.812.72
Placebo3.083.58

Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score

The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible scores range from 33.1 to 77.8, with higher scores indicating more fatigue. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased fatigue. (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization)

,,
Interventionunits on a scale (Mean)
Week 5Week 9
Bupropion 150 mg-2.29-3.28
Bupropion 300 mg-1.11-3.14
Placebo-0.30-3.42

Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 9 Weeks

Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). (NCT03180294)
Timeframe: 9 weeks from start of study treatment (within 21 days of randomization).

,,
InterventionParticipants (Count of Participants)
Severity of dry mouth at its worst = very severeSeverity of decreased appetite at its worst= very severeInterference of decreased appetite with usual or daily activities = very muchFrequency of nausea = almost constantlySeverity of nausea at its worst = very severeSeverity of constipation at its worst = very severeSeverity of dizziness at its worst = very severeInterference of dizziness with usual or daily activities = very muchFrequency of headache = almost constantlySeverity of headache at its worst = very severeInterference of headache with usual or daily activities = very muchSeverity of insomnia at it's worst = very severeInterference of insomnia with usual or daily activities = very much
Bupropion 150 mg0001000000000
Bupropion 300 mg0000000001100
Placebo0000000000011

Perception of Risk vs. Benefit at 9 Weeks

"Participants are asked, Were the benefits of this treatment greater than any side effects?" (NCT03180294)
Timeframe: 9 weeks from start of study treatment (within 21 days of randomization)

,,
InterventionParticipants (Count of Participants)
NoYes
Bupropion 150 mg3730
Bupropion 300 mg3226
Placebo4021

Reviews

12 reviews available for bupropion and Frigidity

ArticleYear
The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis.
    Current neuropharmacology, 2022, Volume: 20, Issue:10

    Topics: Bupropion; Female; Humans; Libido; Sexual Dysfunctions, Psychological; Treatment Outcome

2022
Treatments of Sexual Dysfunction in Opioid Substitution Therapy Patients: A Systematic Review and Meta-Analysis.
    International journal of medical sciences, 2021, Volume: 18, Issue:11

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Humans; Opiate Substitution Treatment; Panax; P

2021
Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.
    Pharmacotherapy, 2013, Volume: 33, Issue:4

    Topics: alpha-MSH; Antidepressive Agents, Second-Generation; Benzimidazoles; Bupropion; Complementary Therap

2013
Managing low sexual desire in women.
    Women's health (London, England), 2011, Volume: 7, Issue:5

    Topics: Bupropion; Dopamine Uptake Inhibitors; Education, Medical, Continuing; Female; Humans; Libido; Menop

2011
Why isn't bupropion the most frequently prescribed antidepressant?
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:5

    Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion;

2005
Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:5

    Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Delayed-Act

2006
Major depressive disorder, antidepressants, and sexual dysfunction.
    The Journal of clinical psychiatry, 2006, Volume: 67 Suppl 6

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B

2006
Sexual side effects of antidepressants: a review.
    Journal of sex & marital therapy, 1996,Fall, Volume: 22, Issue:3

    Topics: Antidepressive Agents, Tricyclic; Benzamides; Bupropion; Female; Humans; Libido; Male; Moclobemide;

1996
Antidepressant-induced sexual dysfunction.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 4

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Libido;

1998
Care of the sexually active depressed patient.
    The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 17

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Clinical Tria

1999
Strategies for the treatment of antidepressant-related sexual dysfunction.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 3

    Topics: Antidepressive Agents; Bupropion; Buspirone; Central Nervous System Stimulants; Depressive Disorder;

2001
The effects of antidepressants on sexual functioning in depressed patients: a review.
    The Journal of clinical psychiatry, 2001, Volume: 62 Suppl 3

    Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind

2001

Trials

19 trials available for bupropion and Frigidity

ArticleYear
Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-01, Volume: 40, Issue:4

    Topics: Adult; Aged; Breast Neoplasms; Bupropion; Cancer Survivors; Delayed-Action Preparations; Dopamine Up

2022
Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women.
    The journal of sexual medicine, 2019, Volume: 16, Issue:12

    Topics: Adult; Bupropion; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female;

2019
The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.
    BJU international, 2010, Volume: 106, Issue:6

    Topics: Adult; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Epidemiologic Methods; Hum

2010
Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study.
    Journal of psychopharmacology (Oxford, England), 2011, Volume: 25, Issue:3

    Topics: Adult; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inhibitor

2011
A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women.
    BJU international, 2010, Volume: 106, Issue:6

    Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Epidemiologic Methods; Female; Humans; Libido; Menstru

2010
Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.
    The Psychiatric quarterly, 2012, Volume: 83, Issue:2

    Topics: Adult; Antidepressive Agents; Binge-Eating Disorder; Body Mass Index; Bupropion; Depressive Disorder

2012
Individual and dyadic barriers to a pharmacotherapeutic treatment of hypoactive sexual desire disorders: results and implications from a small-scale study with bupropion.
    Journal of sex & marital therapy, 2012, Volume: 38, Issue:4

    Topics: Adult; Arousal; Bupropion; Combined Modality Therapy; Delayed-Action Preparations; Dopamine Uptake I

2012
Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:3

    Topics: Adult; Bupropion; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Premenopause; Se

2004
A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:7

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Double-Blind Metho

2005
Bupropion improves sexual functioning in depressed minority women: an open-label switch study.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors;

2006
Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:5

    Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Delayed-Act

2006
A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Majo

2006
Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
    The Journal of clinical psychiatry, 1997, Volume: 58, Issue:12

    Topics: 1-Naphthylamine; Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Bupropion; Delayed

1997
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
    Clinical therapeutics, 1999, Volume: 21, Issue:4

    Topics: Adult; Aged; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inh

1999
Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1999, Volume: 11, Issue:4

    Topics: Adult; Aged; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inh

1999
Effects of bupropion sustained-release on sexual functioning and nocturnal erections in healthy men.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cross-Over Studies; Delayed-Action Prepa

2001
Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study.
    The American journal of psychiatry, 2001, Volume: 158, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Double-Blin

2001
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:7

    Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Bupropion; Comorbidity; Delayed-Action Prepar

2001
Pharmacologic modification of psychosexual dysfunction.
    Journal of sex & marital therapy, 1987,Winter, Volume: 13, Issue:4

    Topics: Adult; Bupropion; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Libido; Male; Middl

1987

Other Studies

18 other studies available for bupropion and Frigidity

ArticleYear
Consultation corner. The latest on female sexual health.
    The Johns Hopkins medical letter health after 50, 2010, Volume: 22, Issue:9

    Topics: Adjuvants, Immunologic; Adult; Antidepressive Agents, Second-Generation; Atrophy; Benzimidazoles; Bu

2010
Improvement in sexual functioning in patients with type 2 diabetes and depression treated with bupropion.
    Diabetes care, 2011, Volume: 34, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Dep

2011
Reproductive life events and sexual functioning in women: case reports.
    CNS spectrums, 2003, Volume: 8, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Female; Hormone Replacement Therapy; Hum

2003
Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:10

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Interac

2003
Weight gain, sexual dysfunction, and bupropion.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:10

    Topics: Ambulatory Care; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Labeling; Humans;

2005
Assessment and management of women's sexual dysfunctions: problematic desire and arousal.
    The journal of sexual medicine, 2005, Volume: 2, Issue:3

    Topics: Adult; Androgens; Bupropion; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopa

2005
Persistent sexual side effects after SSRI discontinuation.
    Psychotherapy and psychosomatics, 2006, Volume: 75, Issue:3

    Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist

2006
Drugs for female sexual dysfunction.
    The Medical letter on drugs and therapeutics, 2007, Apr-23, Volume: 49, Issue:1259

    Topics: Bupropion; Estrogens; Female; Humans; Piperazines; Purines; Sexual Dysfunctions, Psychological; Sild

2007
Psychotropic medications and their effects on sexual function.
    The Journal of clinical psychiatry, 1995, Volume: 56, Issue:11

    Topics: Bupropion; Epilepsy; Female; Humans; Male; Psychotropic Drugs; Selective Serotonin Reuptake Inhibito

1995
Sexual function in patients taking bupropion sustained release.
    The Journal of clinical psychiatry, 1995, Volume: 56, Issue:8

    Topics: Bupropion; Humans; Sexual Behavior; Sexual Dysfunctions, Psychological

1995
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
    The Journal of clinical psychiatry, 1993, Volume: 54, Issue:12

    Topics: Ambulatory Care; Bupropion; Depressive Disorder; Female; Fluoxetine; Humans; Libido; Male; Middle Ag

1993
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1997, Volume: 9, Issue:4

    Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Dis

1997
Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction.
    The Journal of clinical psychiatry, 1998, Volume: 59, Issue:3

    Topics: Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Dose-Response Relationship, Drug; Drug A

1998
Bupropion-SR-induced increased libido and spontaneous orgasm.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1998, Volume: 43, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bupr

1998
Evaluating the tolerability of the newer antidepressants.
    The Journal of nervous and mental disease, 1999, Volume: 187, Issue:2

    Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delaye

1999
Bupropion treatment-related sexual side effects: a case report.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2000, Volume: 45, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Sexual Dysfunctions, Psy

2000
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Delayed-Action Preparatio

2001
Buproprion and sexual dysfunction.
    The American journal of psychiatry, 2002, Volume: 159, Issue:4

    Topics: Bupropion; Delayed-Action Preparations; Humans; Selective Serotonin Reuptake Inhibitors; Sexual Dysf

2002